151.51 -0.74 (-0.48%)
After hours: 4:26PM EDT
|Bid||152.26 x 800|
|Ask||152.26 x 800|
|Day's Range||149.84 - 152.39|
|52 Week Range||70.80 - 168.98|
|Beta (3Y Monthly)||0.24|
|PE Ratio (TTM)||565.99|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Massachusetts-based medical device company Insulet Corporation (NASDAQ: PODD ) said Monday that the FDA has approved its Alternate Controller Enabled Infusion, or ACE, pump. This allows Insulet to ...
Dow Jones futures jumped Wednesday, signaling a stock market rally on Hong Kong and other news. Coupa Software stock soared to a buy zone.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results ...
Today we are going to look at Insulet Corporation (NASDAQ:PODD) to see whether it might be an attractive investment...
The year-over-year improvement in Insulet's (PODD) revenues owing to the solid adoption of Omnipod system, both in the United States and the international markets, encourages us.
Insulet (PODD) delivered earnings and revenue surprises of -33.33% and 8.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
Insulet (PODD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Haemonetics (HAE) is a mid-cap medical technology stock that's on the cusp of breaking out to multi-year highs, notes Mike Cintolo, growth stock specialist and editor of Cabot Top Ten Trader.